Actively Recruiting
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Led by Eli Lilly and Company · Updated on 2026-03-13
28
Participants Needed
2
Research Sites
31 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the study is to assess the amount of Eloralintide (LY3841136) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment and to healthy participants. The study drug will be administered subcutaneously (SC) (under the skin). For each participant, the study will last about 14 weeks, excluding screening.
CONDITIONS
Official Title
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Body weight of 55 kilograms or more and a BMI between 19.0 and 40.0 kg/m², inclusive
- No significant history of spontaneous or alcohol-induced low blood sugar
- For healthy participants: normal kidney function with eGFR of at least 90 mL/min and HbA1c of 6.5% or less
- For participants with severe renal impairment or end-stage kidney disease: stable condition with eGFR less than 30 mL/min or on stable hemodialysis for at least 3 months
- Acceptable blood pressure and pulse rate
- If diagnosed with Type 2 Diabetes Mellitus, HbA1c of 10.0% or less
You will not qualify if you...
- History of chronic liver disease, acute or chronic hepatitis, or autoimmune hepatitis
- Current functioning organ transplant (nonfunctional kidney transplants may be allowed)
- Significant history or current serious disorders affecting cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, blood, skin, or nervous systems that could affect drug processing or pose risks
- For participants with severe renal impairment or end-stage kidney disease: currently receiving continuous hemodialysis or peritoneal dialysis
- Use of any drug for kidney impairment treatment not established in dose and given for at least 7 days before Eloralintide administration
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Floridian Clinical Research, LLC
Miami Lakes, Florida, United States, 33016-1518
Actively Recruiting
2
Omega Research Orlando LLC
Orlando, Florida, United States, 32808
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here